66 studies found for:    "Valganciclovir"
Show Display Options
Rank Status Study
1 Completed
Has Results
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Condition: Cytomegalovirus Infections
Intervention: Drug: Valganciclovir
2 Completed
Has Results
Valganciclovir to Reduce T Cell Activation in HIV Infection
Conditions: HIV Infections;   Cytomegalovirus Infections
Interventions: Drug: Valganciclovir;   Drug: Placebo
3 Completed Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Condition: Cytomegalovirus Infection
Intervention: Drug: Single arm (ganciclovir and valganciclovir)
4 Active, not recruiting Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Condition: Cytomegalovirus Disease
Interventions: Drug: Valganciclovir;   Biological: CMV hyperimmune globulin
5 Recruiting Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
Condition: Infection in Solid Organ Transplant Recipients
Interventions: Drug: Ganciclovir/ Valganciclovir according to SPC;   Drug: Ganciclovir/ Valganciclovir according to PK model
6 Recruiting ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Conditions: Kidney Transplantation;   Epstein-Barr Virus Infections/Complications;   Cytomegalovirus Infections/Complications
Interventions: Drug: Valacyclovir;   Drug: Valganciclovir
7 Terminated Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
Condition: Allogeneic Stem Cell Transplantation
Interventions: Drug: Valganciclovir;   Drug: Ganciclovir
8 Unknown  Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
Conditions: Heart Transplantation;   Cardiac Allograft Vasculopathy;   Cytomegalovirus Infection
Interventions: Drug: Pre-emptive strategy with valganciclovir plus everolimus;   Drug: Prophylaxis with valganciclovir plus mycophenolate;   Drug: Prophylaxis with valganciclovir plus everolimus;   Drug: Pre-emptive mycophenolate
9 Completed
Has Results
A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
Condition: Kidney Transplantation, Cytomegalovirus Infections
Intervention: Drug: valganciclovir [Valcyte]
10 Active, not recruiting
Has Results
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Condition: Cytomegalovirus Infection
Interventions: Drug: Placebo;   Drug: Valganciclovir
11 Completed Valganciclovir in Congenital CMV Infants
Condition: Cytomegalovirus Infections
Interventions: Drug: Valganciclovir;   Drug: Ganciclovir
12 Not yet recruiting Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy
Conditions: Congenital Cytomegalovirus;   Hearing Loss
Interventions: Drug: Valcyte (Valganciclovir hydrochloride) Powder for oral solution;   Drug: Placebo
13 Unknown  Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Condition: Cytomegalovirus Disease
Interventions: Drug: Certican (everolimus) + valganciclovir;   Drug: Valganciclovir
14 Active, not recruiting
Has Results
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
Conditions: EBV Viremia;   CMV Viremia
Interventions: Drug: Valganciclovir;   Drug: Placebo
15 Terminated Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
16 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
17 Withdrawn Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
Condition: Giant Lymph Node Hyperplasia
Intervention: Drug: Valganciclovir
18 Completed Oral Valganciclovir Versus Valacyclovir
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Valganciclovir;   Drug: Valacyclovir
19 Completed
Has Results
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Condition: Cytomegalovirus Infections
Interventions: Drug: valganciclovir;   Other: Placebo
20 Unknown  Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Condition: Chronic Fatigue Syndrome
Intervention: Drug: valganciclovir

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years